Tagged with clinical

Denmark Already one of Europe’s top countries for clinical trials per capita, Denmark has further strengthened its position in recent years. The number of active trials in the country rose from 410 in 2022 to 450 in 2023, backed by increasing citizen participation and a healthcare ecosystem built on trusted health…

Switzerland Alentis Therapeutics, under the leadership of its CEO Roberto Iacone, has made significant strides in advancing innovative therapies targeting Claudin-1, a protein critical in inflammation and cancer. The company’s pipeline includes promising antibody-drug conjugates (ADCs), such as ALE.P02, currently in a Phase I/II clinical trial, and ALE.P03, expected to enter…

Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…

USA The Alzheimer’s Drug Discovery Foundation (ADDF) operates in the critical niche of translational research, attempting to bridge the “Valley of Death” between discovery and commercialisation using a venture philanthropy model that reinvests returns into new science. CEO Mark Roithmayr explains how the ADDF has helped launch major diagnostic tools for…

Saudi Arabia Dr Ahmed Alaskar, Executive Director of KAIMRC, provides an update on the development of Saudi Arabia’s growing biotech ecosystem over the past four years. He shares insights into the Kingdom’s National Biotech Strategy and the development of early-stage clinical trial capabilities. Dr. Alaskar also highlights the Kingdom’s unique advantages in…

Europe While Europe has lost some of its global share of clinical trials to China and the US, it remains a clinical research stronghold. Three years into the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to transform how trials are initiated, designed, and run across the…

Europe To address the European Union’s drop in global share of clinical trials over the past decade, stakeholders are working together to deliver a dynamic, agile, responsive EU clinical trials environment. As Katarina Nedog of the European Federation of Pharmaceutical Industries and Associations (EFPIA) points out in the March 2025 edition…

Denmark A seasoned neuroscience researcher with firsthand experience of both successes and failures in one of biomedicine’s most challenging fields, Johan Luthman is better placed than most to comment on the past, present, and future of Alzheimer’s disease. Luthman, who currently serves as EVP and Head of R&D at Danish neuroscience…

Saudi Arabia Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSHRC), discusses the hospital’s transformation into a world-class medical and research institution, aligning with Saudi Arabia’s Vision 2030. He shares insights into KFSHRC’s pioneering efforts in oncology, transplantation, genetics, and cutting-edge medical technology, as well as its role…

Puerto Rico CDI Labs, founded in 2008 in Mayagüez, Puerto Rico, is a specialized CRO focused on drug development and clinical-stage research, particularly in antibody specificity, biomarker exploration, with emphasis on autoimmune diseases and immunoncology. CDI is leveraging proprietary technologies like its “human on a chip” system to analyze protein interactions and…

Saudi Arabia Mohamed Fawzy, Country President for Pfizer Saudi Arabia, discusses the company’s evolving role in supporting the Kingdom’s rapidly transforming healthcare sector. He shares insights on Pfizer’s local footprint, its contributions to public health through innovative vaccines and oncology treatments, and the company’s commitment to talent development and localization. Fawzy also…

Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…